A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration

NCT03814291 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG: IBI302
DRUG: IBI302
DRUG: IBI302
DRUG: IBI302
DRUG: IBI302
DRUG: IBI302

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.